Victoria Allan

1 month ago | tandfonline.com | Apar Kishor Ganti |Ralph B. D’Agostino |Victoria Allan |Patricia Prince

ABSTRACTAim Assess real-world outcomes of lurbinectedin and other second-line treatments (OST) in adults with small cell lung cancer that progressed on/after chemotherapy. Patients & methods US-based electronic medical data from Flatiron Health (01/01/2013–03/31/2022) were used. Baseline characteristics, including chemotherapy-free interval (CTFI), in patients receiving lurbinectedin or OST were balanced using propensity score (PS) overlap weighting.